D. Gomez and D. N. Lobo, Malignant liver tumours, Surg. Elsevier Ltd, vol.29, pp.632-639, 2011.

M. S. Grandhi, A. K. Kim, S. M. Ronnekleic-kelly, I. R. Kamel, M. A. Ghasebeh et al., Hepatocellular carcinoma: From diagnosis to treatment, Surg Oncol, vol.25, pp.74-85, 2016.

Z. D. Goodman, Neoplasms of the liver, Mod Pathol, vol.20, 2007.

A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA Cancer J Clin, vol.61, pp.69-90, 2011.

E. Maillard, Epidemiology, natural history and pathogenesis of hepatocellular carcinoma

, Cancer/Radiothérapierapie, vol.15, pp.3-6, 2011.

A. Forner, J. M. Llovet, and J. Bruix, Hepatocellular carcinoma, Lancet. Elsevier Ltd, vol.379, pp.1245-55, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01134844

M. C. Kew, Hepatocellular carcinoma: epidemiology and risk factors, J Hepatocell Carcinoma, vol.2014, pp.115-125, 2014.

H. B. El-serag, Hepatocellular carcinoma, N Engl J Med, vol.365, pp.1118-1145, 2011.

C. Bosetti, F. Turati, L. Vecchia, and C. , Hepatocellular carcinoma epidemiology, Best Pract Res Clin Gastroenterol. Elsevier Ltd, 2014.

. Torre-l-a, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global Cancer Statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012.

P. V. Ingle, S. Z. Binti-samsudin, P. Qi, C. , M. Kei et al., Development and novel therapeutics in hepatocellular carcinoma: a review, Ther Clin Risk Manag, vol.445, 2016.

I. Anestopoulos, G. P. Voulgaridou, A. G. Georgakilas, R. Franco, A. Pappa et al., Epigenetic therapy as a novel approach in hepatocellular carcinoma, Pharmacol Ther. Elsevier Inc, vol.145, pp.103-119, 2015.

M. Vullierme, V. Paradis, M. Chirica, D. Castaing, J. Belghiti et al., Hepatocellular carcinoma--what's new?, J Visc Surg, vol.147, pp.1-12, 2010.

J. Barbare, Traitement du carcinome hépatocellulaire. EMC, vol.10, pp.1-8, 2014.

D. Moradpour and H. E. Blum, Pathogenesis of hepatocellular carcinoma, Eur J Gastroenterol Hepatol, vol.17, pp.477-483, 2005.

J. M. Llovet and J. Bruix, Molecular targeted therapies in hepatocellular carcinoma, Hepatology, vol.48, pp.1312-1339, 2008.

S. Vilarinho and T. Taddei, Therapeutic Strategies for Hepatocellular Carcinoma: New Advances and Challenges, Curr Treat Options Gastroenterol, vol.13, pp.219-253, 2015.

P. Bedossa, Fibrose hépatique : physiopathologie , diagnostic , pronostic

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, vol.182, pp.1-9, 2015.

J. Blanc, S. Lepreux, C. Balabaud, P. Bioulac-sage, and . Histophysiologie-hépatique, EMC-Hépatologie, pp.1-13, 2002.

T. Tu, . Budzinska-m-a, A. E. Maczurek, R. Cheng, D. Bartolomeo et al., Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development, Int J Mol Sci, vol.15, pp.9422-58, 2014.

S. S. Thorgeirsson and J. W. Grisham, Molecular pathogenesis of human hepatocellular carcinoma, Nat Genet, vol.31, pp.339-385, 2002.

M. G. Kramer, R. Hernandez-alcoceba, C. Qian, and J. Prieto, Evaluation of hepatocellular carcinoma models for preclinical studies, Drug Discov Today Dis Model, vol.2, pp.41-49, 2005.

A. G. Singal and H. B. El-serag, Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice, Clin Gastroenterol Hepatol, vol.13, pp.2140-2151, 2015.

S. Mittal and H. B. El-serag, Epidemiology of HCC: Consider the Population, J Clin Gastroenterol, vol.47, 2013.

M. Colombo, J. Raoul, R. Lencioni, P. R. Galle, J. Zucman-rossi et al., Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective, Eur J Gastroenterol Hepatol, vol.25, pp.639-651, 2013.

J. C. Trinchet, Hepatocellular carcinoma: Increasing incidence and optimized management

, Gastroenterol Clin Biol, vol.33, pp.830-839, 2009.

T. Clark, S. Maximin, J. Meier, S. Pokharel, P. Bhargava et al., Imaging Diagnosis, Response Assessment, and Treatment, Curr Probl Diagn Radiol, vol.44, pp.479-486, 2015.

V. Cartier and C. Aubé, Diagnosis of hepatocellular carcinoma, Diagn Interv Imaging. Elsevier Masson SAS, vol.95, pp.709-719, 2014.

G. Mazzoccoli, R. Tarquini, A. Valoriani, J. Oben, M. Vinciguerra et al., Management strategies for hepatocellular carcinoma: old certainties and new realities, Clin Exp Med. Springer Milan, 2015.

J. Bruix, G. J. Gores, and V. Mazzaferro, Hepatocellular carcinoma: clinical frontiers and perspectives, Gut, vol.63, pp.844-55, 2014.

A. Singal, M. L. Volk, A. Waljee, R. Salgia, P. Higgins et al., Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis, Aliment Pharmacol Ther, vol.30, pp.37-47, 2009.

S. J. Yu, A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world, Clin Mol Hepatol, vol.22, pp.7-17, 2016.

C. K. Kim, J. H. Lim, and W. J. Lee, Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients, J Ultrasound Med, vol.20, pp.99-104, 2001.

S. Pascual, I. Herrera, and J. Irurzun, New advances in hepatocellular carcinoma, World J Hepatol

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, vol.183, p.421, 2016.

J. M. Llovet, C. Brú, and J. Bruix, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, vol.19, pp.329-338, 1999.

V. A. Saraswat, G. Pandey, and S. Shetty, Treatment Algorithms for Managing Hepatocellular Carcinoma, J Clin Exp Hepatol. Elsevier Ltd, vol.4, pp.80-89, 2014.

M. Maida, E. Orlando, C. Cammà, and G. Cabibbo, Staging systems of hepatocellular carcinoma : A review of literature, World J Gastroenterol, vol.20, pp.4141-4150, 2014.

P. H. Liu, C. Y. Hsu, C. Y. Hsia, Y. H. Lee, C. W. Su et al., Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems, J Hepatol, vol.64, pp.601-608, 2016.

M. Sherman, Staging for hepatocellular carcinoma: An embarrassment of riches, J Hepatol, vol.64, pp.535-536, 2016.

N. Dilou, B. Patouillard, and J. Audigier, Les classifications de prédiction de survie du carcinome hépatocellulaire, Gastroentérologie Clin Biol, vol.28, pp.359-366, 2004.

K. Okuda, T. Ohtsuki, H. Obata, M. Tomimatsu, N. Okazaki et al., Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients, Cancer, vol.56, pp.918-946, 1985.

, The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program, vol.28, pp.751-755, 1998.

S. Chevret, J. Trinchet, D. Mathieu, A. A. Rached, M. Beaugrand et al., A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire, J Hepatol, vol.31, pp.80173-80174, 1999.

T. Leung, A. Tang, B. Zee, W. Y. Lau, P. Lai et al., Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients, Cancer, vol.94, pp.1760-1769, 2002.

M. Minagawa, I. Ikai, Y. Matsuyama, Y. Yamaoka, and M. Makuuchi, Staging of Hepatocellular Carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan, Ann Surg, vol.245, pp.909-922, 2007.

M. Kudo, H. Chung, and Y. Osaki, Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score), J Gastroenterol, vol.38, pp.207-222, 2003.

R. Tateishi, H. Yoshida, S. Shiina, H. Imamura, K. Hasegawa et al., Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients, Gut, vol.54, pp.419-425, 2005.

S. Edge, D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene et al., AJCC Cancer Staging Manual

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.184

C. Y. Hsu, Y. H. Huang, C. Y. Hsia, C. W. Su, H. C. Lin et al., A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system, J Hepatol, vol.53, pp.108-117, 2010.

T. Yau, V. Tang, T. Yao, S. Fan, C. Lo et al., Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma, Gastroenterology, vol.146, pp.1691-1700, 2014.

A. Duseja, Staging of hepatocellular carcinoma, J Clin Exp Hepatol. Elsevier Ltd, vol.4, pp.74-83, 2014.

A. Forner, M. Gilabert, J. Bruix, and J. Raoul, Treatment of intermediate-stage hepatocellular carcinoma, Nat Rev Clin Oncol. Nature Publishing Group, vol.11, pp.525-535, 2014.

J. M. Llovet, D. Bisceglie, A. M. Bruix, J. Kramer, B. S. Lencioni et al., Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, vol.100, pp.698-711, 2008.

F. T. Kolligs, BCLC treatment algorithm and the place of selective internal radiation therapy, Eur J Cancer Suppl. Elsevier B.V, vol.10, pp.27-29, 2012.

. Wörns-m-a and P. R. Galle, Future perspectives in hepatocellular carcinoma, Dig Liver Dis, vol.42, issue.3, p.60521, 2010.

M. Quirk, Y. H. Kim, S. Saab, and E. W. Lee, Management of hepatocellular carcinoma with portal vein thrombosis, World J Gastroenterol, vol.21, pp.3462-3471, 2015.

C. Mosconi, A. Cappelli, C. Pettinato, and R. Golfieri, Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives, World J Hepatol, vol.7, p.738, 2015.

V. Sitruk, O. Seror, and J. Trinchet, Traitement percutané du carcinome hépatocellulaire, EMCHépatologie, pp.1-6, 2004.

M. Giovannini, Le traitement percutané du carcinome hépato-cellulaire: Quelle technique choisir ?, Gastroentérologie Clin Biol, vol.31, pp.347-353, 2007.

A. H. Mahnken, P. Bruners, and R. W. Günther, Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation, Dig Dis, vol.27, pp.148-56, 2009.

A. Orlando, G. Leandro, M. Olivo, A. Andriulli, and M. Cottone, Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials, Am J Gastroenterol, vol.104, pp.514-524, 2009.

Y. K. Cho, J. K. Kim, M. Y. Kim, H. Rhim, and J. K. Han, Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology, vol.49, pp.453-459, 2009.

R. Lencioni, Loco-regional treatment of hepatocellular carcinoma, Hepatology, vol.52, pp.762-773, 2010.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.185

R. Mazzanti, U. Arena, and R. Tassi, Hepatocellular carcinoma: Where are we?, World J Exp Med, vol.6, p.21, 2016.

A. Villanueva, V. Hernandez-gea, and J. M. Llovet, Medical therapies for hepatocellular carcinoma: a critical view of the evidence, Nat Rev Gastroenterol Hepatol. Nature Publishing Group, vol.10, pp.34-42, 2013.

B. Sangro, M. Iñarrairaegui, and J. I. Bilbao, European Association for the Study of the Liver, Cancer (Malignant Neoplasm). PubMed Heal Gloss, vol.56, pp.464-73, 2012.

R. Baskar, A. , K. Yeo, R. Yeoh, and K. , Cancer and Radiation Therapy: Current Advances and Future Directions, Int J Med Sci, vol.9, pp.193-199, 2012.

N. R. Jabir, S. Tabrez, G. M. Ashraf, S. Shakil, and G. Damanhouri, Nanotechnology-based approaches in anticancer research, Int J Nanomedicine, vol.7, pp.4391-408, 2012.

D. Hanahan and R. A. Weinberg, The Hallmarks of, Cancer. Cell, vol.100, pp.57-70, 2000.

S. Vallabhajosula, 18F-Labeled Positron Emission Tomographic Radiopharmaceuticals in Oncology: An Overview of Radiochemistry and Mechanisms of Tumor Localization, Semin Nucl Med, vol.37, pp.400-419, 2007.

B. Theek, L. Y. Rizzo, J. Ehling, F. Kiessling, and T. Lammers, The theranostic path to personalized nanomedicine, Clin Transl imaging, vol.2, pp.66-76, 2014.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell. Elsevier Inc, vol.144, pp.646-674, 2011.

H. Schöder and S. C. Ong, Fundamentals of Molecular Imaging: Rationale and Applications With Relevance for Radiation Oncology, Semin Nucl Med, vol.38, pp.119-128, 2008.

H. Chen, G. Niu, H. Wu, and X. Chen, Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin ? v ? 3, Theranostics, vol.6, pp.78-92, 2016.

N. Withofs, P. Martinive, J. Vanderick, N. Bletard, I. Scagnol et al., 18F]FPRGD2 PET/CT imaging of integrin ?v?3 levels in patients with locally advanced rectal carcinoma, Eur J Nucl Med Mol Imaging, vol.43, pp.654-662, 2015.

S. Vallabhajosula, Molecular imaging -Radiopharmaceuticals for PET and SPECT, 2009.

D. L. Bailey, J. L. Humm, A. Todd-pokropek, A. Aswegen, and . Van, Nuclear Medicine Physics: A Handbook for Teachers and Students

D. L. Bailey, J. L. Humm, A. Todd-pokropek, A. Aswegen, and . Van, International Atomic Energy Agency Publication. Vienna: International Atomic Energy Agency, 2014.

F. Huguet, S. Haverer-guillerm, and M. L. Radiothérapie, EMC -AKOS (Traité Médecine), vol.9, pp.1-6, 2014.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.186

M. L. James and S. S. Gambhir, A molecular imaging primer: modalities, imaging agents, and applications, Physiol Rev, vol.92, pp.897-965, 2012.

G. B. Saha, Basics of PET Imaging, 2016.

C. F. Ramogida and C. Orvig, Tumour targeting with radiometals for diagnosis and therapy, Chem Commun (Camb), vol.49, pp.4720-4759, 2013.

G. B. Saha, Fundamentals of Nuclear Pharmacy

, , 2010.

M. E. Phelps, Positron emission tomography provides molecular imaging of biological processes, Proc Natl Acad Sci U S A, vol.97, pp.9226-9233, 2000.

I. Velikyan, Radionuclides for Imaging and Therapy in Oncology, Cancer Theranostics, pp.285-326, 2014.

K. Leung, Fluoro-2-deoxy-2-D-glucose, Bethesda (MD): National Center for Biotechnology Information (US), vol.18, pp.2004-2013

. Bethesda, National Center for Biotechnology Information (US, pp.4-9, 2004.

T. Ido, C. Wan, V. Casella, J. S. Fowler, A. P. Wolf et al., Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose, J Label Compd Radiopharm, vol.14, pp.175-183, 1978.

P. Blake, B. Johnson, and J. W. Vanmeter, Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT): Clinical Applications, J Neuroophthalmol, vol.23, pp.34-41, 2003.

S. Vallabhajosula, L. Solnes, and B. Vallabhajosula, A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: What is new? Semin Nucl Med, vol.41, pp.246-264, 2011.

R. A. Gatenby and R. J. Gillies, Why do cancers have high aerobic glycolysis?, Nat Rev Cancer, vol.4, pp.891-899, 2004.

R. Boellaard, R. Delgado-bolton, W. Oyen, F. Giammarile, K. Tatsch et al., FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0, Eur J Nucl Med Mol Imaging, vol.42, pp.328-354, 2014.

R. Bilbao, R. Gérolami, M. Bralet, C. Qian, P. L. Tran et al., Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model, Cancer Gene Ther, vol.7, pp.657-662, 2000.

D. Puyraimond-zemmour and S. Vignot, The metabolism of cancer cells: the Warburg effect] Le métabolisme de la cellule tumorale: l'effet Warburg, Oncologie, vol.15, pp.435-440, 2013.

Y. Kuang, S. J. Schomisch, V. Chandramouli, and Z. Lee, Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma, Comp Biochem Physiol -C Toxicol Pharmacol, vol.143, pp.225-231, 2006.

S. S. Gambhir, Molecular imaging of cancer with positron emission tomography, Nat Rev Cancer

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, vol.187, pp.683-693, 2002.

M. Vouche, B. Vanderlinden, P. Delatte, M. Lemort, A. Hendlisz et al., New Imaging Techniques for 90Y Microsphere Radioembolization, J Nucl Med Radiat Ther, vol.2, pp.1-12, 2011.

E. Kawamura, S. Shiomi, K. Kotani, J. Kawabe, A. Hagihara et al., Positioning of 18F-FDG PET imaging in the management algorithm of hepatocellular carcinoma, J Gastroenterol Hepatol, vol.29, pp.1722-1727, 2014.

J. Trojan, O. Schroeder, J. Raedle, R. P. Baum, G. Herrmann et al., Role of 18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma, Am J Gastroenterol, vol.94, pp.749-757, 1999.

O. Detry, L. Govaerts, M. Vandermeulen, N. Meurisse, S. Malenge et al., Prognostic value of 18F-FDG PET/CT in liver transplantation for hepatocarcinoma, World J Gastroenterol, vol.21, pp.3049-54, 2015.

S. R. Banerjee and M. G. Pomper, Clinical applications of Gallium-68, Appl Radiat Isot. Elsevier, vol.76, 2013.

D. Ersahin, I. Doddamane, and D. Cheng, Targeted Radionuclide Therapy, Cancers (Basel), vol.3, pp.3838-3855, 2011.

C. Lamesa, A. Rauscher, F. Lacoeuille, M. Desruet, and B. Guillet, Faivre-Chauvet A. 68Ga somatostatin analog radiolabelling: The radiopharmacist's point of view, Médecine Nucléaire. Elsevier Masson SAS, vol.39, pp.3-10, 2015.

M. Fani, J. P. André, and H. R. Maecke, 68Ga-PET: a powerful generator-based alternative to cyclotronbased PET radiopharmaceuticals, Contrast Media Mol Imaging, vol.3, pp.53-63, 2008.

M. Fani, H. R. Maecke, and S. M. Okarvi, Radiolabeled peptides: valuable tools for the detection and treatment of cancer, Theranostics, vol.2, pp.481-501, 2012.

R. P. Baum, F. Rösch, and . Theranostics, Gallium-68, and Other Radionuclides -A Pathway to Personalized Diagnosis and Treatment. Recent Results in Cancer Research, 2013.

M. U. Khan, S. Khan, S. El-refaie, Z. Win, and D. Rubello, Al-Nahhas a. Clinical indications for Gallium-68 positron emission tomography imaging, Eur J Surg Oncol. Elsevier Ltd, vol.35, pp.561-567, 2009.

M. Hamoudeh, M. A. Kamleh, R. Diab, and H. Fessi, Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer, Adv Drug Deliv Rev, vol.60, pp.1329-1375, 2008.

J. A. Seibert, X-ray imaging physics for nuclear medicine technologists. Part 1: Basic principles of x-ray production, J Nucl Med Technol, vol.32, pp.139-147, 2004.

L. Wojnárovits, A. Vértes, S. Nagy, Z. Klencsár, R. Lovas et al., Handbook of Nuclear Chemistry, pp.1263-1331, 2011.

B. Kanyár and G. J. K?teles, Dosimetry and Biological Effects of Ionizing Radiation, Vértes A, Nagy Verger Elise | Les, p.68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.188

S. , K. Z. Lovas, R. Rösch, and F. , Handbook of Nuclear Chemistry, pp.2211-2257, 2011.

U. Häfeli, Radioactive Microspheres for Medical Applications, pp.213-248, 2002.

K. A. Pilones, C. Vanpouille-box, and S. Demaria, Combination of Radiotherapy and Immune Checkpoint Inhibitors, Semin Radiat Oncol. Elsevier, vol.25, pp.28-33, 2015.

D. Eriksson and T. Stigbrand, Radiation-induced cell death mechanisms, Tumor Biol, vol.31, pp.363-372, 2010.

C. Lavelle and N. Foray, Chromatin structure and radiation-induced DNA damage: From structural biology to radiobiology, Int J Biochem Cell Biol. Elsevier Ltd, vol.49, pp.84-97, 2014.

L. J. Eccles, P. O'neill, and M. E. Lomax, Delayed repair of radiation induced clustered DNA damage: Friend or foe?, Mutat Res -Fundam Mol Mech Mutagen. Elsevier B.V, vol.711, pp.134-141, 2011.

A. I. Kassis, Therapeutic radionuclides: biophysical and radiobiologic principles, Semin Nucl Med, vol.38, pp.358-66, 2008.

. Volkert-w-a, W. F. Goeckeler, and G. J. Ehrhardt, Ketring a R. Therapeutic radionuclides: production and decay property considerations, J Nucl Med, vol.32, pp.174-185, 1991.

T. Das and M. R. Pillai, Options to meet the future global demand of radionuclides for radionuclide therapy, Nucl Med Biol. Elsevier Inc, vol.40, pp.23-32, 2013.

Y. Cordoliani and I. V. Chapitre, Interaction des rayonnements ionisants avec la matière, Feuill Radiol, vol.42, pp.437-441, 2002.

M. R. Mcdevitt, G. Sgouros, R. D. Finn, J. L. Humm, J. G. Jurcic et al., Radioimmunotherapy with alpha-emitting nuclides, Eur J Nucl Med, vol.25, pp.1341-1351, 1998.

M. Chérel, S. Gouard, J. Gaschet, C. Saï-maurel, F. Bruchertseifer et al., 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma, J Nucl Med, vol.54, pp.1597-604, 2013.

S. C. Srivastava and L. F. Mausner, Therapeutic Radionuclides: Production, Physical Characteristics, and Applications, Therapeutic Nuclear Medicine, pp.11-50, 2014.

C. Alberti, From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy, Eur Rev Med Parmacological Sci, vol.16, pp.1925-1933, 2012.

S. S. Kelkar and T. M. Reineke, Theranostics: Combining imaging and therapy, Bioconjug Chem, vol.22, pp.1879-1903, 2011.

H. M. Warenius, Technological challenges of theranostics in oncology, Expert Opin Med Diagn, vol.3, pp.381-393, 2009.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.189

S. Jeelani, J. Reddy, R. Maheswaran, T. Asokan, G. Dany et al., Theranostics: A tresured tailor for tomorrow, J Pharm Bioallied Sci, vol.6, pp.6-8, 2014.

S. M. Janib, A. S. Moses, and J. A. Mackay, Imaging and drug delivery using theranostic nanoparticles, Adv Drug Deliv Rev. Elsevier B.V, vol.62, pp.1052-1063, 2010.

B. Sumer and J. Gao, Theranostic nanomedicine for cancer, Nanomedicine (Lond), vol.3, pp.137-177, 2008.

X. Chen and S. Wong, Cancer Theranostics: An Introduction, Cancer Theranostics, pp.3-8, 2014.

R. P. Baum and H. R. Kulkarni, Theranostics: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy -the bad berka experience, Theranostics, vol.2, pp.437-447, 2012.

, Velikyan I. 68Ga-Based Radiopharmaceuticals: Production and Application Relationship, Molecules, vol.20, pp.12913-12943, 2015.

C. Müller, C. Vermeulen, U. Köster, K. Johnston, A. Türler et al., Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm Chem. EJNMMI Radiopharmacy and Chemistry, vol.1, p.5, 2017.

M. W. Brechbiel, Targeted ?-therapy: past, present, future? Dalt Trans, vol.4918, 2007.

S. C. Srivastava, Paving the way to personalized medicine: Production of some promising theragnostic radionuclides at Brookhaven national laboratory, Semin Nucl Med, vol.42, pp.151-163, 2012.

Y. Lee and J. M. Jeong, Inorganic Radionuclides for Nuclear Medicine Therapy, Therapeutic Nuclear Medicine, pp.151-163, 2014.

E. Deutsch, K. Libson, J. L. Vanderheyden, and H. R. Ketring-a-r,-maxon, The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine, Int J Rad Appl Instrum B, vol.13, issue.86, pp.90027-90036, 1986.

S. Liu, The role of coordination chemistry in the development of target-specific radiopharmaceuticals, Chem Soc Rev, vol.33, pp.445-461, 2004.

C. Müller, M. Bunka, J. Reber, C. Fischer, K. Zhernosekov et al., Promises of cyclotronproduced 44Sc as a diagnostic match for trivalent ?--emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate, J Nucl Med, vol.54, pp.2168-74, 2013.

C. Müller, M. Bunka, S. Haller, U. Köster, V. Groehn et al., Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice, J Nucl Med, vol.55, pp.1658-64, 2014.

J. M. Connett, C. J. Anderson, L. W. Guo, S. W. Schwarz, K. R. Zinn et al., Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu, Proc Natl Acad Sci U S A, vol.93, pp.6814-6818, 1996.

K. Zimmermann, J. Grünberg, M. Honer, S. Ametamey, and P. A. Schubiger, Novak-Hofer I. Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: Selection of copper ligands and PET imaging, Nucl Med Biol, vol.30, p.19, 2003.

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.190

P. M. Smith-jones, B. Stolz, C. Bruns, R. Albert, H. W. Reist et al., Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptorpositive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies, J Nucl Med, vol.35, pp.317-325, 1994.

F. Rösch, H. Herzog, C. Plag, B. Neumaier, U. Braun et al., Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography, Eur J Nucl Med, vol.23, pp.958-966, 1996.

R. P. Baum, Therapeutic Nuclear Medicine

R. P. Baum, L. W. Brady, H. Heilmann, M. Molls, and C. Nieder, , 2014.

E. Verger, P. Drion, G. Meffre, C. Bernard, L. Duwez et al., 68Ga and 188Re StarchBased Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies, PLoS One, vol.11, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01398433

J. Idée, S. Louguet, S. Ballet, and C. Corot, Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint, Quant Imaging Med Surg, vol.3, pp.292-299, 2013.

L. Mishra, T. Banker, J. Murray, S. Byers, A. Thenappan et al., Liver stem cells and hepatocellular carcinoma, Hepatology, vol.49, pp.318-329, 2009.

C. Hennequin, L. Quero, and S. Rivera, Cancer Radiother, vol.15, pp.39-42, 2011.

A. Kennedy, S. Nag, R. Salem, R. Murthy, A. J. Mcewan et al., Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium, Int J Radiat Oncol Biol Phys, vol.68, pp.13-23, 2007.

R. Murthy, R. Nunez, J. Szklaruk, M. J. Wallace, A. Cohen et al., , p.90

, Microspheres Therapy for Hepatic Malignancy: Devices, Indications, Technical Considerations, and Potential Complications, vol.25, pp.41-55, 2005.

R. J. Lewandowski, K. T. Sato, B. Atassi, R. K. Ryu, . Nemcek-a-a et al., Radioembolization with 90Y microspheres: angiographic and technical considerations, Cardiovasc Intervent Radiol, vol.30, pp.571-92, 2007.

E. Rio, F. Mornex, D. Peiffert, and A. Huertas, Radiothérapie des tumeurs hépatiques, Cancer / Radiother. Elsevier Masson SAS, vol.20, 2016.

T. S. Lawrence, J. M. Robertson, M. S. Anscher, R. L. Jirtle, W. D. Ensminger et al., Hepatic toxicity resulting from cancer treatment, Int J Radiat Oncol Biol Phys, vol.30, pp.1237-1285, 1995.

J. Meza-junco, A. J. Montano-loza, D. M. Liu, M. B. Sawyer, V. G. Bain et al., Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?, Cancer Treat Rev. Elsevier Ltd, vol.38, pp.54-62, 2012.

. Tsochatzis-e-a, E. M. Fatourou, C. K. Triantos, and A. K. Burroughs, Transarterial therapies for hepatocellular carcinoma, Recent Results Cancer Res, vol.190, pp.195-206, 2013.

J. Geschwind, R. Salem, B. I. Carr, M. C. Soulen, K. G. Thurston et al., , p.90

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.191

, microspheres for the treatment of hepatocellular carcinoma, Gastroenterology, vol.127, pp.194-205, 2004.

R. Gallicchio, A. Nardelli, P. Mainenti, A. Nappi, D. Capacchione et al., Therapeutic Strategies in HCC : Radiation Modalities, Biomed Res Int, p.11, 2016.

S. Ma, B. Jiao, X. Liu, H. Yi, D. Kong et al., Approach to radiation therapy in hepatocellular carcinoma, Cancer Treat Rev. Elsevier Ltd, vol.36, pp.157-63, 2010.

S. Ibrahim, R. Lewandowski, K. Sato, V. Gates, L. Kulik et al., Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review, World J Gastroenterol, vol.14, pp.1664-1673, 2008.

A. S. Kennedy, C. Nutting, D. Coldwell, J. Gaiser, and C. Drachenberg, Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers, Int J Radiat Oncol Biol Phys, vol.60, pp.1552-63, 2004.

J. H. Muller and P. H. Rossier, A New Method for the Treatment of Cancer of the Lungs by Means of Artificial Radioactivity: (Zn63 and Au198) First experimental and clinical studies, Acta radiol, vol.35, pp.449-468, 1951.

A. S. Kennedy, W. A. Dezarn, P. Mcneillie, and . Microspheres, Liver Radioembolization with 90Y Microspheres. 2nd Editio, pp.1-10, 2014.

A. Dogliotti, L. Caldarola, F. Badellino, A. Cavalli, and P. Calderini, Endo-arterial regional injection of radioisotopes in the treatment of malignant tumours, Int J Appl Radiat Isot, vol.17, pp.51-59, 1966.

L. Caldarola, U. Rosa, F. Badellino, S. Sosi, and A. Cavalli, Preparation of 32-P labelled resin microspheres for radiation treatment of tumours by intra-arterial injection, Minerva Nucl, vol.8, pp.169-74, 1964.

Y. Kao, J. D. Steinberg, Y. Tay, G. Lim, J. Yan et al., Post-radioembolization yttrium-90 PET/CT -part 1: Diagnostic reporting, EJNMMI Res, vol.3, p.56, 2013.

R. Salem and K. G. Thurston, Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction, J Vasc Interv Radiol, vol.17, pp.1571-93, 2006.

Y. H. Kao, General theory of predictive dosimetry for yttrium-90 radioembolization to sites other than the liver, Cardiovasc Intervent Radiol, vol.37, pp.1114-1117, 2014.

K. Muylle, J. Nguyen, D. Wind, A. Meuleman, N. Delatte et al., Radioembolization of the spleen: A revisited approach for the treatment of malignant lymphomatous splenomegaly, Cardiovasc Intervent Radiol, vol.36, pp.1155-1160, 2013.

N. Hamoui, V. L. Gates, J. Gonzalez, R. J. Lewandowski, and R. Salem, Radioembolization of renal cell carcinoma using yttrium-90 microspheres, J Vasc Interv Radiol. Elsevier, vol.24, pp.298-300, 2013.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.192

J. Ricke, O. Großer, and H. Amthauer, Y90-radioembolization of lung metastases via the bronchial artery: A report of 2 cases, Cardiovasc Intervent Radiol, vol.36, pp.1664-1669, 2013.

J. R. Kallini, A. Gabr, R. Salem, and R. J. Lewandowski, Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma, Adv Ther. Springer Healthcare, vol.33, pp.699-714, 2016.

R. M. Hickey, R. J. Lewandowski, and R. Salem, Yttrium-90 radioembolization for hepatocellular carcinoma, Semin Nucl Med. Elsevier, vol.46, pp.105-108, 2016.

R. J. Lewandowski, J. Geschwind, E. Liapi, and R. Salem, Transcatheter intraarterial therapies: rationale and overview, Radiology, vol.259, pp.641-657, 2011.

M. F. Bozkurt, B. V. Salanci, and Ö. U?ur, Intra-Arterial Radionuclide Therapies for Liver Tumors, Semin Nucl Med, vol.46, pp.324-339, 2016.

J. Raoul, E. Boucher, Y. Rolland, and E. Garin, Treatment of hepatocellular carcinoma with intraarterial injection of radionuclides, Nat Rev Gastroenterol Hepatol. Nature Publishing Group, vol.7, pp.41-50, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00742471

C. Breedis and G. Young, The blood supply of neoplasms in the liver, Am J Pathol, vol.30, pp.969-77, 1954.

N. B. Ackerman, Experimental studies on the circulation dynamics of intrahepatic tumor blood supply, Cancer, vol.29, pp.435-444, 1972.

G. Vesselle, I. Petit, S. Boucebci, T. Rocher, S. Velasco et al., Radioembolization with yttrium-90 microspheres work up: Practical approach and literature review, Diagn Interv Imaging. Elsevier Masson SAS, vol.96, pp.547-562, 2015.

L. Uliel, H. D. Royal, M. D. Darcy, A. Sharma, and N. E. Saad, From the Angio Suite to the ?-Camera: Vascular Mapping and 99mTc-MAA Hepatic Perfusion Imaging Before Liver Radioembolization -A Comprehensive Pictorial Review, J Nucl Med, vol.53, pp.1736-1747, 2012.

H. R. Bierman, R. L. Byron, K. H. Kelley, and A. Grady, Studies on the Blood Supply of Tumors in Man. III. Vascular Patterns of the Liver by Hepatic Arteriography in Vivo, J Natl Cancer Inst, vol.12, pp.107-138, 1951.

W. Bult, M. Vente, B. Zonnenberg, A. Van-het-schip, and J. Nijsen, Microsphere radioembolization of liver malignancies: current developments, Q J Nucl Med Mol imaging, vol.53, pp.325-335, 2009.

R. J. Blanchard, I. Grotenhuis, J. W. Lafave, C. W. Frye, and J. Perry, Treatment of experimental tumors: Utilization of radioactive microspheres, Arch Surg, vol.89, pp.406-416, 1964.

R. J. Blanchard, J. W. Lafave, Y. S. Kim, C. S. Frye, W. P. Ritchie et al., Treatment of patients with advanced cancer utilizing Y90 microspheres, Cancer, vol.18, pp.375-380, 1965.

I. M. Ariel, Treatment of Inoperable Primary Pancreatic and Liver Cancer By the Intra-Arterial Administration of Radioactive Isotopes (Y90 Radiating Microspheres), Ann Surg, vol.162, pp.267-78, 1965.

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques 193

I. M. Ariel and G. T. Pack, Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy, Cancer, vol.20, pp.793-804, 1967.

E. D. Grady, Internal radiation therapy of hepatic cancer, Dis Colon Rectum, vol.22, pp.371-375, 1979.

B. Sangro, Chemoembolization and radioembolization, Best Pract Res Clin Gastroenterol. Elsevier Ltd, vol.28, pp.909-919, 2014.

A. Raza and G. K. Sood, Hepatocellular carcinoma review: Current treatment, and evidence-based medicine, World J Gastroenterol, vol.20, pp.4115-4127, 2014.

F. Chegai, A. Orlacchio, S. Merolla, S. Monti, and L. Mannelli, Intermediate hepatocellular carcinoma : the role of transarterial therapy, Hepatic Oncol, vol.2, pp.399-408, 2015.

V. Mitra and J. Metcalf, Functional anatomy and blood supply of the liver, Anaesth Intensive Care Med. Elsevier Ltd, vol.13, pp.52-53, 2012.

D. Ribatti, A. Vacca, B. Nico, D. Sansonno, and F. Dammacco, Angiogenesis and anti-angiogenesis in hepatocellular carcinoma, Cancer Treat Rev, vol.32, pp.437-481, 2006.

R. J. Lewandowski and R. Salem, Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver, Semin Intervent Radiol, vol.23, pp.64-72, 2006.

F. Nijsen, D. Rook, C. Brandt, R. Meijer, H. Dullens et al., Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study, Eur J Nucl Med, vol.28, pp.743-749, 2001.

J. Folkman, What is the evidence that tumors are angiogenesis dependent?, J Natl Cancer Inst, vol.82, pp.4-6, 1990.

A. Kennedy, Radioembolization of hepatic tumors, J Gastrointest Oncol, vol.5, pp.178-89, 2014.

K. H. Bae, H. J. Chung, and T. G. Park, Nanomaterials for cancer therapy and imaging, Mol Cells, vol.31, pp.295-302, 2011.

M. Kohandel, M. Kardar, M. Milosevic, and S. Sivaloganathan, Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies, Phys Med Biol, vol.52, pp.3665-77, 2007.

R. Pang and R. Poon, Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma, Cancer Lett, vol.242, pp.151-67, 2006.

N. B. Ackerman and P. A. Hechmer, The blood supply of experimental liver metastases. V. Increased tumor perfusion with epinephrine, Am J Surg, vol.140, pp.625-631, 1980.

J. Trojan, S. Zangos, and A. A. Schnitzbauer, Diagnostics and Treatment of Hepatocellular Carcinoma in 2016 : Standards and Developments, Visc Med, vol.32, pp.116-120, 2016.

Z. F. Yang and R. Poon, Vascular changes in hepatocellular carcinoma, Anat Rec (Hoboken), vol.291, pp.721-755, 2008.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.194

W. Lau, A. S. Kennedy, Y. H. Kim, H. K. Lai, R. Lee et al., Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres, Int J Radiat Oncol Biol Phys, vol.82, pp.401-408, 2012.

A. Braat, M. Smits, M. Braat, A. F. Van-den-hoven, J. F. Prince et al., 90Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments, J Nucl Med, vol.56, pp.1079-87, 2015.

F. Giammarile, L. Bodei, C. Chiesa, G. Flux, F. Forrer et al., EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds, Eur J Nucl Med Mol Imaging, vol.38, pp.1393-406, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00814020

H. Ngan and W. Peh, Arteriovenous shunting in hepatocellular carcinoma: Its prevalence and clinical significance, Clin Radiol, vol.52, pp.36-40, 1997.

J. Chen, J. Chai, H. Huang, W. Shen, and L. San-kan, Proximal arterioportal shunting associated with hepatocellular carcinoma: features revealed by dynamic helical CT, Am J Roentgenol, vol.172, pp.403-407, 1999.

R. Salem and K. G. Thurston, Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations, J Vasc Interv Radiol, vol.17, pp.1251-78, 2006.

H. Ahmadzadehfar, H. Biersack, and S. Ezziddin, Radioembolization of liver tumors with yttrium-90 microspheres, Semin Nucl Med. Elsevier Inc, vol.40, pp.105-126, 2010.

B. I. Carr, Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients, Liver Transpl, vol.10, pp.107-117, 2004.

S. A. Gulec, M. L. Sztejnberg, J. A. Siegel, T. Jevremovic, and M. Stabin, Hepatic Structural Dosimetry in 90Y Microsphere Treatment: A Monte Carlo Modeling Approach Based on Lobular Microanatomy, J Nucl Med, vol.51, pp.301-310, 2010.

A. M. Campbell, I. H. Bailey, and M. A. Burton, Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy, Phys Med Biol, vol.45, pp.1023-1056, 2000.

J. Högberg, M. Rizell, R. Hultborn, J. Svensson, O. Henrikson et al., Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased spherecluster frequency and absorbed dose inhomogeneity, EJNMMI Phys, vol.2, p.10, 2015.

L. Bester, B. Meteling, D. Boshell, T. C. Chua, and D. L. Morris, Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature, J Med Imaging Radiat Oncol, vol.58, pp.341-352, 2014.

L. Prompers, J. Bucerius, B. Brans, Y. Temur, L. Berger et al., Selective internal radiation therapy (SIRT) in primary or secondary liver cancer, vol.55, pp.253-260, 2011.

A. M. Covey, L. Brody, G. I. Maluccio-m-a,-getrajdman, and K. T. Brown, Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, vol.195, pp.542-547, 2002.

N. A. Michels, Newer anatomy of the liver and its variant blood supply and collateral circulation, Am J Surg, vol.112, pp.337-347, 1966.

S. Favelier, T. Germain, P. Y. Genson, J. P. Cercueil, A. Denys et al., Anatomy of liver arteries for interventional radiology, Diagn Interv Imaging. Elsevier Masson SAS, vol.96, pp.537-583, 2015.

A. Denys, A. Sauvanet, S. Wicky, P. Schnyder, and J. Belghiti,

, J Radiol, vol.83, pp.205-218, 2002.

R. Saiz-mendiguren, J. Arias, I. Vivas, and J. I. Bilbao, Vascular Anatomy and Its Implication in Radioembolization, p.90

. Microspheres and . Editio, , pp.27-40, 2014.

N. Michels, Collateral arterial pathways to the liver after ligation of the hepatic artery and removal of the celiac axis, Cancer, vol.6, pp.708-732, 1953.

J. R. Hiatt, J. Gabbay, and R. W. Busuttil, Surgical anatomy of the hepatic arteries in 1000 cases, Ann Surg, vol.220, pp.50-52, 1994.

J. Cazejust, B. Bessoud, N. Colignon, C. Garcia-alba, O. Planché et al., Vascularisation artérielle du carcinome hépatocellulaire : des artères classiques aux plus rares, J Radiol Diagnostique Interv. Elsevier Masson SAS, vol.95, pp.30-39, 2014.

S. I. Seldinger, Catheter replacement of the needle in percutaneous arteriography, Acta radiol, vol.39, pp.368-76, 1953.

J. E. Dancey, . Shepherd-f-a, K. Paul, K. W. Sniderman, S. Houle et al., Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres, J Nucl Med, vol.41, pp.1673-81, 2000.

R. Salem, R. J. Lewandowski, K. T. Sato, B. Atassi, R. K. Ryu et al., Technical aspects of radioembolization with 90Y microspheres, Tech Vasc Interv Radiol, vol.10, pp.12-29, 2007.

R. Sacco, V. Mismas, S. Marceglia, A. Romano, L. Giacomelli et al., Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives, World J Gastroenterol, vol.21, pp.6518-6525, 2015.

H. Ellis, Anatomy of the liver, Surgery. Elsevier Ltd, vol.29, pp.589-592, 2011.

F. Boudghene and M. Tassart, Imagerie de l'aorte abdominale normale, EMC -Radiol Imag MÉDICALE Cardiovasc -Thorac -Cervicale, 2009.

N. P. Rhodes, . Anatomy, A. Physiology-;-taktak, P. Ganney, D. Long et al., Clinical Engineering -A Handbook for Clinical and Biomedical Engineers, pp.3-20, 2014.

F. Nelson and C. T. Blauvelt, A Manual of Orthopaedic Terminology (Eighth Edition), Nelson FR, pp.209-282, 2015.

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.196

A. Riaz, R. Awais, and R. Salem, Side effects of yttrium-90 radioembolization, Front Oncol, vol.4, p.198, 2014.

F. I. Chou, K. C. Fang, C. Chung, W. Y. Lui, C. W. Chi et al., Lipiodol uptake and retention by human hepatoma cells, Nucl Med Biol, vol.22, pp.379-386, 1995.

N. Lepareur, V. Ardisson, N. Noiret, and E. Garin, Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside, Int J Mol Imaging, vol.2012, issue.188, p.278306, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00866975

B. Lambert and C. Van-de-wiele, Treatment of hepatocellular carcinoma by means of radiopharmaceuticals, Eur J Nucl Med Mol Imaging, vol.32, pp.980-989, 2005.

T. Carlier, T. Eugène, C. Bodet-milin, E. Garin, C. Ansquer et al., Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT, EJNMMI Res, vol.3, p.11, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00806787

C. L. Wright, J. Zhang, M. F. Tweedle, M. Knopp, and N. C. Hall, Theranostic Imaging of Yttrium-90, Biomed Res Int, vol.2015, pp.1-11, 2015.

F. Rösch, F. R. Knapp, A. Radionuclide-generators-;-vértes, S. Nagy, Z. Klencsár et al., Handbook of Nuclear Chemistry, pp.1935-1976, 2011.

F. Rösch and R. P. Baum, Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS, Dalton Trans, vol.40, pp.6104-6115, 2011.

P. Stevenson and W. Nervik, The Radiochemistry of the Rare Earths, Scandium, Yttrium, and Actinium [Internet]. NAS-NS 302. Subcommittee on Radiochemistry, 1961.

R. Murthy, A. Habbu, and R. Salem, Trans-arterial hepatic radioembolisation of yttrium-90 microspheres, Biomed Imaging Interv J, vol.2, p.43, 2006.

F. F. Knapp, M. Pillai, O. Jr, J. A. Dash, and A. , Re-emergence of the important role of radionuclide generators to provide diagnostic and therapeutic radionuclides to meet future research and clinical demands, J Radioanal Nucl Chem, vol.302, pp.1053-1068, 2014.

M. Cremonesi, C. Chiesa, L. Strigari, M. Ferrari, F. Botta et al., Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective, Front Oncol, vol.4, p.210, 2014.

J. Vente-m-a-d,-nijsen, T. C. De-wit, J. H. Seppenwoolde, G. C. Krijger, and P. R. Seevinck, Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs, Eur J Nucl Med Mol Imaging, vol.35, pp.1259-71, 2008.

C. Chiesa, M. Mira, M. Maccauro, R. Romito, C. Spreafico et al., A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres, Q J Nucl Med Mol Imaging, vol.56, pp.503-509, 2012.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques 197

R. J. Lewandowski, A. Riaz, R. K. Ryu, M. F. Mulcahy, K. T. Sato et al., Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study, J Vasc Interv Radiol, vol.20, pp.1557-63, 2009.

F. Kraeber-bodere, E. Garin, and J. Vuillez, Radiopharmaceutiques à visée thérapeutique : indications, précautions d'emploi et principaux résultats, EMC -Radiol Imag médicale Principes Tech -Radioprot, vol.8, issue.13, pp.60169-60176, 2013.

. Vente-m-a-d, M. Wondergem, I. Van-der-tweel, J. Van-den-bosch-m-a-a, and M. Lam, Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis, Eur Radiol, vol.19, pp.951-960, 2009.

A. S. Kennedy, W. A. Dezarn, P. Mcneillie, and B. Sangro, Dosimetry and Dose Calculation, Liver Radioembolization with 90Y Microspheres. 2nd Editio, pp.53-61, 2014.

K. Sato, R. J. Lewandowski, J. T. Bui, R. Omary, R. D. Hunter et al., Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization, Cardiovasc Intervent Radiol, vol.29, pp.522-531, 2006.

S. B. Paul and H. Sharma, Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma, J Clin Exp Hepatol. Elsevier Ltd, vol.4, 2014.

J. Arbizu, M. Rodriguez-fraile, J. M. Martí-climent, I. Domínguez-prado, and C. Vigil, Nuclear Medicine Procedures for Treatment Evaluation and Administration, Liver Radioembolization with 90Y Microspheres. Second Edi, pp.63-75, 2014.

R. Salem and K. G. Thurston, Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics, J Vasc Interv Radiol, vol.17, pp.1425-1464, 2006.

J. I. Bilbao and M. F. Reiser, Liver Radioembolization with 90Y Microspheres

. Editio, J. I. Bilbao, and M. F. Reiser, , 2014.

A. El-fouly, J. Ertle, E. Dorry, A. Shaker, M. K. Dechêne et al., In intermediate stage hepatocellular carcinoma: Radioembolization with yttrium 90 or chemoembolization?, Liver Int, pp.627-635, 2014.

J. Steel, A. Baum, and B. Carr, Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere), Psychooncology, vol.13, pp.73-82, 2004.

C. Aubé, A. Bouvier, J. Lebigot, L. Vervueren, V. Cartier et al., Traitement radiologique du CHC : la radiologie interventionnelle au centre de la prise en charge, J Radiol Diagnostique Interv, vol.96, pp.180-191, 2015.

R. Salem and R. D. Hunter, Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review, Int J Radiat Oncol Biol Phys, vol.66, pp.83-91, 2006.

K. Memon, R. J. Lewandowski, A. Riaz, and R. Salem, Yttrium 90 Microspheres for the Treatment of Hepatocellular Carcinoma, pp.207-224, 2013.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques

H. H. Tam and A. Al-nahhas, Treatment of liver tumours with yttrium radioembolisation, Clin Transl Imaging, vol.2, pp.165-182, 2014.

L. M. Kulik, B. I. Carr, M. F. Mulcahy, R. J. Lewandowski, B. Atassi et al., Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology, vol.47, pp.71-81, 2008.

M. Iñarrairaegui, K. G. Thurston, J. I. Bilbao, D. 'avola, D. Rodriguez et al., Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis, J Vasc Interv Radiol, vol.21, pp.1205-1212, 2010.

M. C. Kew, Serum aminotransferase concentration as evidence of hepatocellular damage, Lancet, vol.355, pp.591-592, 2000.

S. Berthélémy and . Le-bilan-hépatique, Actual Pharm. Elsevier Masson SAS, vol.54, pp.59-61, 2015.

C. Buffet, Élévation des Transaminases en hépatologie, EMC -AKOS (Traité Médecine), vol.9, pp.1-7, 2014.

F. A. Rochling, Evaluation of Abnormal Liver Tests, Clin Cornerstone, vol.3, pp.1-12, 2001.

A. Blann, What is the purpose of liver function tests?, Nurs Times, vol.110, pp.17-19, 2013.

A. Perry and P. Labrune, Troubles constitutionnels du métabolisme de la bilirubine, EMCHépatologie, vol.11, pp.1-6, 2016.

I. Campbell, Liver: metabolic functions, Anaesth Intensive Care Med, vol.7, pp.51-54, 2006.

P. Ge, S. Du, and Y. Mao, Advances in preoperative assessment of liver function, Hepatobiliary Pancreat Dis Int, vol.13, pp.361-70, 2014.

A. I. Gomaa, S. A. Khan, E. Leen, I. Waked, and S. D. Taylor-robinson, Diagnosis of Hepatocellular carcinoma, World J Gastroenterol, vol.15, pp.1301-1314, 2009.

E. S. Bialecki, D. Bisceglie, and A. M. , Diagnosis of hepatocellular carcinoma, HPB (Oxford), vol.7, pp.26-34, 2005.

T. G. Bird, P. Dimitropoulou, R. M. Turner, S. J. Jenks, P. Cusack et al., Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection, PLoS One, vol.11, 2016.

D. M. Liu, R. Salem, J. T. Bui, A. Courtney, O. Barakat et al., Angiographic considerations in patients undergoing liver-directed therapy, J Vasc Interv Radiol, vol.16, pp.911-935, 2005.

P. M. Paprottka, T. F. Jakobs, M. F. Reiser, and R. T. Hoffmann, Practical vascular anatomy in the preparation of radioembolization, Cardiovasc Intervent Radiol, vol.35, pp.454-462, 2012.

A. Riaz, L. M. Kulik, M. F. Mulcahy, R. J. Lewandowski, and R. Salem, Yttrium-90 radioembolization in the management of liver malignancies, Semin Oncol. Elsevier Inc, vol.37, pp.94-101, 2010.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques

R. Salem, R. J. Lewandowski, V. L. Gates, C. W. Nutting, R. Murthy et al., Research reporting standards for radioembolization of hepatic malignancies, J Vasc Interv Radiol, vol.22, pp.265-78, 2011.

H. Ahmadzadehfar, A. Sabet, K. Biermann, M. Muckle, H. Brockmann et al., The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment, J Nucl Med, vol.51, pp.1206-1218, 2010.

F. R. Knapp, J. Kropp, and K. Liepe, Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy, Therapeutic Nuclear Medicine, pp.51-81, 2014.

E. Garin, L. Lenoir, Y. Rolland, E. J. Mesbah, H. Laffont et al., Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary Results, J Nucl Med, vol.53, pp.255-263, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00866987

H. Ilhan, A. Goritschan, P. Paprottka, T. F. Jakobs, W. P. Fendler et al., Predictive value of 99mTc-labelled MAA scintigraphy for 90Y-microspheres distribution in radioembolization treatment with resin microspheres in primary and secondary hepatic tumors, J Nucl Med, vol.56, pp.1654-60, 2015.

M. Wondergem, M. Smits, M. Elschot, M. Verkooijen, H. M. Van-den-bosch-m-a-a et al., 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization, J Nucl Med, vol.54, pp.1294-301, 2013.

M. Elschot, J. Nijsen, M. Lam, M. Smits, J. F. Prince et al., Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (166)Ho-microspheres, Eur J Nucl Med Mol Imaging, vol.41, issue.99m, pp.1965-75, 2014.

T. Gupta, S. Virmani, T. M. Neidt, B. Szolc-kowalska, K. T. Sato et al., MR Tracking of Ironlabeled Glass Radioembolization Microspheres during Transcatheter Delivery to Rabbit VX2 Liver Tumors: Feasibility Study 1, Radiology, vol.249, pp.845-854, 2008.

B. L. Dunfee, A. Riaz, R. J. Lewandowski, S. Ibrahim, M. F. Mulcahy et al., Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival, J Vasc Interv Radiol, vol.21, pp.90-95, 2010.

R. Salem, R. J. Lewandowski, B. Atassi, S. C. Gordon, V. L. Gates et al., Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival, J Vasc Interv Radiol, vol.16, pp.1627-1666, 2005.

. Dezarn-w-a, J. T. Cessna, W. Feng, V. L. Gates, and J. Halama, Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies, Med Phys, vol.38, p.4824, 2011.

. Gulec-s-a, G. Mesoloras, and M. Stabin, Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations, J Nucl Med, vol.47, pp.1209-1211, 2006.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques

J. K. Mikell, A. Mahvash, W. Siman, F. Mourtada, and S. C. Kappadath, Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90)Y microsphere selective internal radiation therapy, EJNMMI Phys. EJNMMI Physics, vol.2, p.16, 2015.

, SIR-Spheres microspheres (Yttrium-90 Microspheres) -Users instructions, SIRTeX Medical Ltd

L. B. Harrison, M. Chadha, R. J. Hill, K. Hu, and D. Shasha, Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes, Oncologist, vol.7, pp.492-508, 2002.

L. Harrison and K. Blackwell, Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?, Oncologist, vol.9, pp.31-40, 2004.

M. Bernardini, C. Smadja, M. Faraggi, S. Orio, A. Petitguillaume et al., Liver Selective Internal Radiation Therapy with (90)Y resin microspheres: Comparison between pretreatment activity calculation methods, Phys Med, vol.30, pp.752-64, 2014.

E. Garin, Y. Rolland, E. J. Icard, N. Lenoir, L. Laffont et al., Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis, J Nucl Med, vol.56, pp.339-346, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01128116

C. Chiesa, M. Mira, M. Maccauro, C. Spreafico, R. Romito et al., Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology, Eur J Nucl Med Mol Imaging, vol.42, pp.1718-1738, 2015.

A. Riaz, R. Lewandowski, L. Kulik, and R. Salem, Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors, Q J Nucl Med Mol imaging, vol.53, pp.311-316, 2009.

V. L. Gates, A. Esmail, K. Marshall, S. Spies, and R. Salem, Internal Pair Production of 90Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept, J Nucl Med, vol.52, pp.72-76, 2011.

S. A. Padia, A. Alessio, S. W. Kwan, D. H. Lewis, S. Vaidya et al., Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis, J Vasc Interv Radiol. Elsevier, vol.24, pp.1147-1153, 2013.

R. Lhommel, P. Goffette, M. Van-den-eynde, J. F. Pauwels, S. Bilbao et al., Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT, Eur J Nucl Med Mol Imaging, vol.36, p.1696, 2009.

Y. S. Song, J. C. Paeng, H. Kim, J. W. Chung, G. J. Cheon et al., PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy, Medicine (Baltimore), vol.94, p.945, 2015.

R. Salem, R. J. Lewandowski, M. F. Mulcahy, A. Riaz, R. K. Ryu et al., Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques 201 term outcomes, vol.138, pp.52-64, 2010.

J. Bruix, M. Sherman, J. M. Llovet, M. Beaugrand, R. Lencioni et al., Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference, J Hepatol, vol.35, pp.421-430, 2001.

, World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment, 1979.

P. Therasse, S. G. Arbuck, J. Eisenhauer-e-a,-wanders, R. S. Kaplan, and L. Rubinstein, New guidelines to evaluate the response to treatment in solid Tumors, J Natl Cancer Inst, vol.92, pp.205-216, 2000.

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer. Elsevier Ltd, vol.45, pp.228-247, 2009.

S. Delumeau, J. Lebigot, C. Ridereau-zins, A. Bouvier, J. Boursier et al., Aspects et évaluation post-thérapeutiques des lésions du foie après traitement non chirurgical, J Radiol, vol.92, pp.632-638, 2011.

R. Lencioni and J. M. Llovet, Modified RECIST (mRECIST) Assessment for hepatocellular carcinoma, Semin Liver Dis, vol.30, pp.52-60, 2010.

R. Salem and R. J. Lewandowski, Chemoembolization and radioembolization for hepatocellular carcinoma, Clin Gastroenterol Hepatol. Elsevier Inc, vol.11, pp.604-611, 2013.

B. Sangro, L. Carpanese, R. Cianni, R. Golfieri, D. Gasparini et al., Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, vol.54, pp.868-78, 2011.

P. Hilgard, M. Hamami, A. Fouly, . El, A. Scherag et al., Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, vol.52, pp.1741-1749, 2010.

R. Golfieri, J. I. Bilbao, L. Carpanese, R. Cianni, D. Gasparini et al., Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma, J Hepatol. European Association for the Study of the Liver, pp.1-9, 2013.

W. Lau, S. Ho, T. Leung, M. Chan, R. Ho et al., Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90 yttrium microspheres, Int J Radiat Oncol Biol Phys, vol.40, pp.583-592, 1998.

C. Spreafico, M. Maccauro, V. Mazzaferro, and C. Chiesa, The dosimetric importance of the number of (90)Y microspheres in liver transarterial radioembolization (TARE), Eur J Nucl Med Mol Imaging, vol.41, pp.634-642, 2014.

V. Mazzaferro, C. Sposito, S. Bhoori, R. Romito, C. Chiesa et al., Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study, Hepatology, vol.57, pp.1826-1837, 2013.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.202

R. Salem, R. J. Lewandowski, L. Kulik, E. Wang, A. Riaz et al., Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology. Elsevier Inc, vol.140, pp.497-507, 2011.

F. T. Kolligs, J. I. Bilbao, T. Jakobs, M. Iñarrairaegui, J. M. Nagel et al., Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma, Liver Int, vol.35, pp.1715-1721, 2015.

M. B. Pitton, R. Kloeckner, C. Ruckes, G. M. Wirth, W. Eichhorn et al., Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma, Cardiovasc Intervent Radiol, vol.38, pp.352-360, 2015.

V. Kousik, P. Promila, R. Verma, and A. Gupta, Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases, Indian J Gastroenterol. Indian Journal of Gastroenterology, vol.35, pp.179-185, 2016.

J. Y. Young, T. K. Rhee, B. Atassi, V. L. Gates, L. Kulik et al., Radiation Dose Limits and Liver Toxicities Resulting from Multiple Yttrium-90 Radioembolization Treatments for Hepatocellular Carcinoma, J Vasc Interv Radiol, vol.18, pp.1375-1382, 2007.

J. Y. Ni, L. F. Xu, W. D. Wang, H. L. Sun, and Y. T. Chen, Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: A meta-analysis, World J Gastroenterol, vol.20, pp.17206-17217, 2014.

R. J. Lewandowski, L. M. Kulik, . Riaz-a, S. Senthilnathan, M. F. Mulcahy et al., A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization, Am J Transplant, vol.9, pp.1920-1928, 2009.

. Kooby-d-a, V. Egnatashvili, S. Srinivasan, A. Chamsuddin, . Delman-k-a et al., Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma, J Vasc Interv Radiol, vol.21, pp.224-254, 2010.

B. I. Carr, V. Kondragunta, S. C. Buch, and R. A. Branch, Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: A two-cohort study, Cancer, vol.116, pp.1305-1314, 2010.

L. E. Moreno-luna, J. D. Yang, W. Sanchez, R. Paz-fumagalli, D. M. Harnois et al., Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma, Cardiovasc Intervent Radiol, vol.36, pp.714-723, 2013.

J. Idée and B. Guiu, Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review, Crit Rev Oncol Hematol. Elsevier Ireland Ltd, vol.88, pp.530-579, 2013.

S. Bhattacharya, J. R. Novell, M. C. Winslet, and K. Hobbs, Iodized oil in the treatment of hepatocellular carcinoma, Br J Surg, vol.81, pp.1563-1571, 1994.

J. L. Raoul, D. Guyader, J. F. Bretagne, R. Duvauferrier, P. Bourguet et al., Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support, J Nucl Med, vol.35, pp.1782-1789, 1994.

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.203

J. L. Raoul, D. Guyader, J. F. Bretagne, J. F. Heautot, R. Duvauferrier et al., Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma, Hepatology, vol.26, pp.1156-61, 1997.

A. Kumar, D. N. Srivastava, T. Chau, C. S. Bal, P. Chandra et al., Inoperable Hepatocellular Carcinoma: Transarterial 188Re HDD-Labeled Iodized Oil for TreatmentProspective Multicenter Clinical Trial, Radiology, vol.243, pp.509-519, 2007.

B. Lambert, K. Bacher, and L. Defreyne, Rhenium-188 based radiopharmaceuticals for treatment of liver tumours, Q J Nucl Med Mol imaging, vol.53, pp.305-310, 2009.

S. Wang, W. Lin, W. Lui, M. Chen, Z. Tsai et al., Hepatic Artery Injection of Yttrium-90-Lipiodol: Biodistribution in Rats with Hepatoma, J Nucl Med, vol.37, pp.332-337, 1996.

J. Yu, U. O. Häfeli, M. Sands, and Y. Dong, 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer, Appl Radiat Isot, vol.58, pp.64-66, 2003.

T. Das, S. Chakraborty, H. D. Sarma, M. Venkatesh, and S. Banerjee, Preparation of 166Ho-oxinelipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer, Nucl Med Commun, vol.30, pp.362-367, 2009.

S. Subramanian, T. Das, S. Chakraborty, H. D. Sarma, S. Banerjee et al., Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study, Cancer BiotherRadiopharm, vol.25, pp.539-543, 2010.

A. Lintia-gaultier, C. Perret, C. Ansquer, T. Eugene, F. Kraeber-bodere et al., Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience, Nucl Med Commun, vol.34, pp.674-681, 2013.

L. Andreana, G. Isgrò, L. Marelli, N. Davies, D. Yu et al., Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: transarterial radio-embolisation of HCC, Cancer Treat Rev. Elsevier Ltd, vol.38, pp.641-650, 2012.

S. Jouneau, E. Vauléon, S. Caulet-maugendre, E. Polard, A. C. Volatron et al., 131I-labeled lipiodol-induced interstitial pneumonia: A series of 15 cases, Chest, vol.139, pp.1463-1469, 2011.

A. K. Padhy, Rhenium-188 Lipiodol for the treatment of Hepatocellular Carcinoma (HCC), Therapeutic Nuclear Medicine, pp.393-404, 2014.

S. Wang, W. Lin, M. Chen, B. Hsieh, L. Shen et al., Biodistribution of rhenium-188 Lipiodol infused via the hepatic artery of rats with hepatic tumours, Eur J Nucl Med, vol.23, pp.13-20, 1996.

S. J. Wang, W. Y. Lin, M. N. Chen, B. T. Hsieh, L. H. Shen et al., Radiolabelling of Lipiodol with generator-produced 188Re for hepatic tumor therapy, Appl Radiat Isot, vol.47, pp.267-71, 1996.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.204

J. M. Jeong, Y. J. Kim, Y. S. Lee, J. I. Ko, M. Son et al., Re-TDD, for the treatment of liver cancer, Nucl Med Biol, vol.28, issue.188, pp.197-204, 2001.

J. Lee-y-s, K. Jm, C. Yj, P. Jw, . Jh et al., Synthesis of 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer, Nucl Med Commun, vol.23, pp.237-242, 2002.

A. Boschi, L. Uccelli, A. Duatti, P. Colamussi, C. Cittanti et al., A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma, Nucl Med Commun, vol.25, pp.691-700, 2004.

N. Lepareur, E. Garin, N. Noiret, and J. Y. Herry, A kit formulation for the labelling of lipiodol with generator-produced 188Re, J Label Compd Radiopharm, vol.47, pp.857-867, 2004.

T. Luo, B. Hsieh, S. Wang, W. Lin, T. Lee et al., Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection, Nucl Med Biol, vol.31, pp.671-678, 2004.

J. C. Paeng, J. M. Jeong, C. J. Yoon, Y. Lee, Y. Suh et al., Lipiodol solution of Re-188-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: Preclinical study in a rabbit liver cancer model, J Nucl Med, vol.44, pp.2033-2038, 2003.

F. Sundram, T. Chau, P. Onkhuudai, P. Bernal, and A. K. Padhy, Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, vol.31, pp.250-257, 2004.

B. Lambert, K. Bacher, L. Defreyne, F. Gemmel, H. Van-vlierberghe et al., 188Re-HDD/Lipiodol Therapy for Hepatocellular Carcinoma: A Phase I Clinical Trial, J Nucl Med, vol.46, pp.60-66, 2005.

P. Bernal, J. Raoul, G. Vidmar, E. Sereegotov, F. X. Sundram et al., Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study, Int J Radiat Oncol Biol Phys, vol.69, pp.1448-55, 2007.

B. Lambert and J. De-klerk, Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy, Nucl Med Commun, vol.27, pp.223-229, 2006.

E. Garin, N. Noiret, C. Malbert, N. Lepareur, A. Roucoux et al., Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs, Eur J Nucl Med Mol Imaging, vol.31, pp.542-548, 2004.

N. Lepareur, V. Ardisson, N. Noiret, E. Boucher, R. J. Clément et al., Automation of labelling of Lipiodol with high-activity with high-activity generator-produced 188Re, Appl Radiat Isot, vol.69, pp.426-430, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00752790

P. Tabrizian, S. Roayaie, and M. E. Schwartz, Current management of hepatocellular carcinoma, World J Gastroenterol, vol.20, pp.10223-10237, 2014.

, European Directorate for the Quality of Medicines, 2010.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques 205

J. Vucina and D. Lukic, Radionuclidic generators for the production of technetium-99m and rhenium-188, Facta Univ -Ser Physics, vol.2, pp.235-243, 2002.

A. Boschi, L. Uccelli, M. Pasquali, A. Duatti, A. Taibi et al., 188W/188Re Generator System and Its Therapeutic Applications, J Chem, p.14, 2014.

F. Rösch, 68Ge/68Ga Generators and 68Ga Radiopharmaceutical Chemistry on Their Way into a New Century, J Postgrad Med Educ Res, vol.47, pp.18-25, 2013.

F. Lacoeuille, F. Hindré, B. Denizot, F. Bouchet, P. Legras et al., New starch-based radiotracer for lung perfusion scintigraphy, Eur J Nucl Med Mol Imaging, vol.37, pp.146-55, 2010.

F. Lacoeuille, F. Hindré, M. C. Venier-julienne, M. Sergent, F. Bouchet et al., A starchbased microparticulate system dedicated to diagnostic and therapeutic nuclear medicine applications, Biomaterials. Elsevier Ltd, vol.32, pp.7999-8009, 2011.

B. Denizot, F. Lacoeuille, L. Jeune, J. Hindré, and F. , New compositions based on polysaccharides grafted by polyamine or polysulphurised compounds. WO2009013358, 2007.

I. Velikyan, Prospective of 68Ga-Radiopharmaceutical development, Theranostics, vol.4, pp.47-80, 2014.

U. Abram and A. R. , Technetium and rhenium -Coordination chemistry and nuclear medical applications, J Braz Chem Soc, vol.17, pp.1486-1500, 2006.

E. Dadachova and S. Mirzadeh, The Role of Tin in the Direct Labelling of Proteins with Rhenium-188, Nucl Med Biol, vol.24, pp.605-613, 1997.

C. Vanpouille-box, F. Lacoeuille, J. Roux, C. Aubé, E. Garcion et al., Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model, PLoS One, vol.6, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00741696

F. P. Difilippo, S. Patel, K. Asosingh, and S. C. Erzurum, Small-animal imaging using clinical positron emission tomography/computed tomography and super-resolution, Mol Imaging, vol.11, pp.210-219, 2012.

H. Ahmadzadehfar, M. Muckle, A. Sabet, K. Wilhelm, C. Kuhl et al., The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects, Eur J Nucl Med Mol Imaging, vol.39, pp.309-315, 2012.

C. Bal and A. Kumar, Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy, Trop Gastroenterol, vol.29, pp.62-70, 2008.

F. Roesch and P. J. Riss, The renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry, Curr Top Med Chem, vol.10, pp.1633-1668, 2010.

Y. Liu, B. Zha, H. Zhang, X. Zhu, Y. Li et al., Characteristic gene expression profiles in the progression from liver cirrhosis to carcinoma induced by diethylnitrosamine in a rat

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.206

, J Exp Clin Cancer Res, vol.28, pp.1-16, 2009.

G. Chen, Z. K. Dai, R. G. Liang, S. J. Xiao, S. Q. He et al., Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters, Exp Ther Med, vol.3, pp.285-292, 2012.

L. S. Fournier, C. A. Cuenod, C. De-bazelaire, N. Siauve, C. Rosty et al., Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent, Eur Radiol, vol.14, pp.2125-2133, 2004.

A. Parvinian, L. C. Casadaban, and R. C. Gaba, Development, growth, propagation, and angiographic utilization of the rabbit VX2 model of liver cancer: A pictorial primer and "how to" guide, Diagnostic Interv Radiol, vol.20, pp.335-340, 2014.

D. J. Hnatowich, Labeling of tin-soaked albumin microspheres with 68Ga, J Nucl Med, vol.17, pp.57-61, 1976.

S. Ament, S. Maus, H. Reber, H. G. Buchholz, N. Bausbacher et al., Lung Ventilation/Perfusion Imaging Using 68Ga Aerosol (Galligas) and 68Ga-Labeled Macroaggregated Albumin. Recent Results Cancer Res, vol.194, pp.301-317, 2013.

H. N. Wagner, D. C. Sabiston, M. Iio, J. G. Mcafee, J. K. Meyer et al., Regional Pulmonary Blood Flow in Man by Radioisotope Scanning, JAMA, vol.187, pp.601-603, 1964.

A. Amor-coarasa, A. Milera, D. Carvajal, S. Gulec, and A. J. Mcgoron, Lyophilized Kit for the Preparation of the PET Perfusion Agent [68Ga]-MAA, Int J Mol Imaging, vol.2014, pp.1-7, 2014.

G. A. Even and M. A. Green, Gallium-68-labeled Macroaggregated Human Serum Albumin, 68Ga-MAA, Int J Rad Appl Instrum B, vol.16, pp.319-321, 1989.

C. J. Mathias and M. A. Green, A convenient route to [68Ga]Ga-MAA for use as a particulate PET perfusion tracer, Appl Radiat Isot, vol.66, pp.1910-1912, 2008.

S. Maus, H. Buchholz, S. Ament, C. Brochhausen, N. Bausbacher et al., Labelling of commercially available human serum albumin kits with 68Ga as surrogates for 99mTc-MAA microspheres, Appl Radiat Isot Incl data Instrum methods use Agric Ind Med. Elsevier, vol.69, pp.171-175, 2011.

M. S. Hofman, J. Beauregard, T. W. Barber, O. C. Neels, P. Eu et al., 68Ga PET/CT VentilationPerfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy, J Nucl Med, vol.52, pp.1513-1519, 2011.

L. Roux, P. Siva, S. Steinfort, D. P. Callahan, J. Eu et al., Correlation of 68Ga Ventilation-Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function, J Nucl Med, vol.56, pp.1718-1723, 2015.

L. Roux, P. Leong, T. L. Barnett, S. A. Hicks, R. J. Callahan et al., Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery. Cancer Imaging, Cancer Imaging, vol.16, p.24, 2016.

S. Y. Wu, J. W. Kuo, T. K. Chang, R. S. Liu, R. C. Lee et al., Preclinical characterization of 18F-MAA, a novel PET surrogate of 99mTc-MAA, Nucl Med Biol. Elsevier Inc, vol.39, pp.1026-1033, 2012.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques 207

P. Carberry, B. P. Lieberman, K. Ploessl, S. R. Choi, D. N. Haase et al., New F-18 prosthetic group via oxime coupling, Bioconjug Chem, vol.22, pp.642-653, 2011.

Z. Li and P. S. Conti, Radiopharmaceutical chemistry for positron emission tomography, Adv Drug Deliv Rev. Elsevier B.V, vol.62, pp.1031-1051, 2010.

G. Wunderlich, J. Pinkert, M. Andreeff, M. Stintz, F. F. Knapp et al., Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy, Appl Radiat Isot, vol.52, pp.63-71, 2000.

K. Liepe, C. Brogsitter, J. Leonhard, G. Wunderlich, R. Hliscs et al., Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization, Jpn J Clin Oncol, vol.37, pp.942-50, 2007.

H. Ni, C. Yu, S. Chen, L. Chen, C. Lin et al., Preparation and imaging of rhenium-188 labeled human serum albumin microsphere in orthotopic hepatoma rats, Appl Radiat Isot, vol.99, pp.117-121, 2015.

O. S. Grosser, J. Ruf, D. Kupitz, A. Pethe, G. Ulrich et al., Pharmacokinetics of 99mTc-MAA and 99mTc-HSA-Microspheres used in pre-Radioembolization Dosimetry -Influence on the Liver-Lung Shunt, J Nucl Med, vol.57, pp.925-927, 2016.

G. Wunderlich, E. Schiller, R. Bergmann, and H. J. Pietzsch, Comparison of the stability of Y-90-, Lu-177-and Ga-68-labeled human serum albumin microspheres (DOTA-HSAM), Nucl Med Biol. Elsevier Inc, vol.37, pp.861-867, 2010.

S. J. Wagner and M. J. Welch, Gallium-68 Labeling of Albumin and Albumin Microspheres, J Nucl Med, vol.20, pp.428-433, 1979.

R. L. Hayes, J. E. Carlton, and Y. Kuniyasu, A new method for labeling microspheres with 68Ga, Eur J Nucl Med, vol.6, pp.531-533, 1981.

D. A. Chesler, C. Hales, D. J. Hnatowich, and B. Hoop, Three-dimensional reconstruction of lung perfusion image with positron detection, J Nucl Med, vol.16, pp.80-82, 1975.

J. Nijsen, B. Zonnenberg, J. Woittiez, I. Swildens-vans-woudenberg, P. Van-rijk et al., Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques, Eur J Nucl Med, vol.26, pp.699-704, 1999.

B. Brans, O. Linden, F. Giammarile, J. Tennvall, and C. Punt, Clinical applications of newer radionuclide therapies, Eur J Cancer, vol.42, pp.994-1003, 2006.

X. D. Wang, R. J. Yang, X. C. Cao, J. Tan, and B. Li, Dose delivery estimated by bremsstrahlung imaging and partition model correlated with response following intra-arterial radioembolization with 32p-glass microspheres for the treatment of hepatocellular carcinoma, J Gastrointest Surg, vol.14, pp.858-866, 2010.

X. Wang, Z. Yin, Y. Peng, Y. Liu, P. Wu et al., Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy, World J Gastroenterol, vol.14, pp.518-541, 2008.

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.208

D. Zhang, L. Liu, J. Wan, M. Li, and Q. , Effect of phosphorus-32 glass microspheres on human hepatocellular carcinoma in nude mice, World J Gastroenterol, vol.10, pp.1551-1554, 2004.

L. Liu, Z. Jiang, G. Teng, J. Song, D. Zhang et al., Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma, World J Gastroenterol, vol.5, pp.492-505, 1999.

L. Li, L. Yan, and X. Chen, The side effect and complication of intraarterial phosphorus-32 glass microspheres for patients with advanced hepatoma

, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi Chinese J Biomed Eng, vol.14, p.376, 1997.

L. Yan, L. Li, and S. Chen,

, Zhonghua Wai Ke Za Zhi, vol.34, pp.526-535, 1996.

L. Yan, Z. Li, L. Li, L. Wang, W. Lu et al., The relationship between effects and radiation doses of intra-arterial phosphorus-32 glass microspheres embolization therapy for patients with advanced liver cancer

, Zhonghua Wai Ke Za Zhi, vol.38, pp.837-877, 2000.

U. O. Häfeli, W. K. Roberts, G. J. Pauer, S. K. Kraeft, and R. M. Macklis, Stability of biodegradable radioactive rhenium (Re-186 and Re-188) microspheres after neutron-activation, Appl Radiat Isot, vol.54, pp.869-79, 2001.

S. D. Conzone, U. O. Häfeli, D. E. Day, and G. J. Ehrhardt, Preparation and properties of radioactive rhenium glass microspheres intended for in vivo radioembolization therapy, J Biomed Mater Res, vol.42, pp.617-625, 1998.

U. O. Häfeli, S. Casillas, D. W. Dietz, G. J. Pauer, L. A. Rybicki et al., Hepatic tumor radioembolization in a rat model using radioactive rhenium (186Re/188Re) glass microspheres, Int J Radiat Oncol Biol Phys, vol.44, issue.98, pp.554-563, 1999.

G. Wunderlich, A. Drews, and J. Kotzerke, A kit for labeling of [188Re] human serum albumin microspheres for therapeutic use in nuclear medicine, Appl Radiat Isot, vol.62, pp.915-923, 2005.

K. Liepe and J. Kotzerke, Advantage of 188Re-Radiopharmaceuticals in Hepatocellular Cancer and Liver Metastases, J Nucl Med, vol.46, pp.1407-1415, 2005.

M. L. Nowicki, J. B. Cwikla, A. J. Sankowski, S. Shcherbinin, J. Grimmes et al., Initial Study of Radiological and Clinical Efficacy Radioembolization Using 188Re-Human Serum Albumin (HSA) Microspheres in Patients with Progressive, Unresectable Primary or Secondary Liver Cancers, Med Sci Monit Int Med J Exp Clin Res, vol.20, pp.1353-1362, 2014.

R. J. Mumper, U. Y. Ryo, and M. Jay, Neutron-activated holmium-166-Poly(L-lactic acid) microspheres: A potential agent for the internal radiation therapy of hepatic tumors, J Nucl Med, vol.32, pp.2139-2143, 1991.

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques 209

R. J. Mumper and M. Jay, Biodegradable radiotherapeutic polyester microspheres: optimization and in-vitro/in-vivo evaluation, J Control Release, vol.18, p.90165, 1992.

J. F. Nijsen, M. J. Van-steenbergen, H. Kooijman, H. Talsma, L. M. Kroon-batenburg et al., Characterization of poly(L-lactic acid) microspheres loaded with holmium acetylacetonate, Biomaterials, vol.22, pp.3073-81, 2001.

J. Nijsen, J. Seppenwoolde, T. Havenith, C. Bos, C. Bakker et al., Liver tumors: MR imaging of radioactive holmium microspheres--phantom and rabbit study, Radiology, vol.231, pp.491-499, 2004.

A. Chopra, Loaded poly(L-lactic acid) microspheres. In: 2004-2013 B (MD): NC for BI (US), editor. Molecular Imaging and Contrast Agent Database (MICAD)

. Bethesda, National Center for Biotechnology Information (US), pp.1-4, 2010.

T. C. Vente-m-a-d,-de-wit, J. Van-den-bosch-m-a-a, W. Bult, P. R. Seevinck, and . Zonnenberg-b-a, Holmium-166 poly(L-lactic acid) microsphere radioembolisation of the liver: technical aspects studied in a large animal model, Eur Radiol, vol.20, pp.862-871, 2010.

M. Cosimelli, The evolution of radioembolisation, Lancet Oncol. Elsevier Ltd, vol.13, pp.965-971, 2012.

M. Smits, J. Nijsen, J. Van-den-bosch-m-a-a, M. Lam, D. Vente-m-a et al., Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial, J Exp Clin Cancer Res, vol.29, p.70, 2010.

M. Smits, J. Nijsen, J. Van-den-bosch-m-a-a, M. Lam, D. Vente-m-a et al., Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study, Lancet Oncol, vol.13, pp.1025-1059, 2012.

J. F. Prince, R. Van-rooij, G. H. Bol, H. W. De-jong, M. A. Van-den-bosch et al., Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres, J Nucl Med, vol.56, pp.817-823, 2015.

T. Ahmed and B. Aljaeid, Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery, Drug Des Devel Ther, vol.10, pp.483-507, 2016.

B. C. Cho, E. H. Kim, H. J. Choi, J. H. Kim, J. K. Roh et al., A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma, Yonsei Med J, vol.46, pp.799-805, 2005.

J. H. Sohn, H. J. Choi, J. T. Lee, J. D. Lee, J. H. Kim et al., Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma, Oncology, vol.76, pp.1-9, 2009.

A. Bujold and L. Dawson, Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma, Cancer Radiother. Elsevier Masson SAS, vol.15, pp.54-63, 2011.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.210

W. Bult, H. De-leeuw, O. M. Steinebach, M. J. Van-der-bom, H. T. Wolterbeek et al., Radioactive holmium acetylacetonate microspheres for interstitial microbrachytherapy: an in vitro and in vivo stability study, Pharm Res, vol.29, pp.827-863, 2012.

F. W. Zielinski and M. Kasprzyk, Synthesis and quality control testing of 32P labeled ion exchange resin microspheres for radiation therapy of hepatic neoplasms, Int J Appl Radiat Isot, vol.34, pp.90026-90027, 1983.

R. N. Aravalli, J. Golzarian, and E. Cressman, Animal models of cancer in interventional radiology, Eur Radiol, vol.19, pp.1049-53, 2009.

R. N. Aravalli, C. J. Steer, M. B. Sahin, and E. Cressman, Stem cell origins and animal models of hepatocellular carcinoma, Dig Dis Sci, vol.55, pp.1241-50, 2010.

Y. Li, Z. Tang, and J. Hou, Hepatocellular carcinoma: insight from animal models, Nat Rev Gastroenterol Hepatol. Nature Publishing Group, vol.9, pp.32-43, 2012.

L. Wu, Z. Tang, and Y. Li, Experimental models of hepatocellular carcinoma: developments and evolution, J Cancer Res Clin Oncol, vol.135, pp.969-81, 2009.

P. Newell, A. Villanueva, S. L. Friedman, K. Koike, and J. M. Llovet, Experimental models of hepatocellular carcinoma, J Hepatol, vol.48, pp.858-79, 2008.

M. Leenders and M. W. Nijkamp, Borel Rinkes IH. Mouse models in liver cancer research: A review of current literature, World J Gastroenterol, vol.14, pp.6915-6938, 2008.

F. Heindryckx, I. Colle, V. Vlierberghe, and H. , Experimental mouse models for hepatocellular carcinoma research, Int J Exp Pathol, vol.90, pp.367-86, 2009.

X. Li, X. Zhou, Y. Guan, Y. Wang, D. Scutt et al., N-nitrosodiethylamine-induced pig liver hepatocellular carcinoma model: radiological and histopathological studies, Cardiovasc Intervent Radiol, vol.29, pp.420-428, 2006.

B. C. Tennant, S. F. Peek, J. R. Jacob, S. Menne, and W. E. Hornbuckle, Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection, Gastroenterology, vol.127, pp.283-293, 2004.

J. Cao, E. Yang, J. Su, Y. Li, and P. Chow, The tree shrews: adjuncts and alternatives to primates as models for biomedical research, J Med Primatol, vol.32, pp.123-130, 2003.

Y. Li, D. Wan, W. Wei, J. Su, J. Cao et al., Candidate genes responsible for human hepatocellular carcinoma identified from differentially expressed genes in hepatocarcinogenesis of the tree shrew (Tupaia belangeri chinesis), Hepatol Res, vol.38, pp.85-95, 2008.

L. Balemans, V. Mattijssen, P. Steerenberg, B. Van-driel, D. Mulder et al., Den Otter W. Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated, Cancer Immunol Immunother, vol.37, pp.7-14, 1993.

C. K. Lindsay, C. C. Sinha, and U. Thorgeirsson, Morphological study of vascular dissemination in a metastatic hepatocellular carcinoma model in the monkey, Hepatology, vol.26, pp.1209-1215, 1997.

J. R. Foster, Spontaneous and drug-induced hepatic pathology of the laboratory beagle dog, the Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.211

, cynomolgus macaque and the marmoset, Toxicol Pathol, vol.33, pp.63-74, 2005.

H. S. Lam and Z. Gong, Modeling liver cancer using zebrafish: A comparative oncogenomics approach, Cell Cycle, vol.5, pp.573-577, 2006.

A. Thalheimer, C. Otto, M. Bueter, B. Illert, S. Gattenlohner et al., Tumor cell dissemination in a human colon cancer animal model: Orthotopic implantation or intraportal injection?, Eur Surg Res, vol.42, pp.195-200, 2009.

C. M. Bagi and C. J. Andresen, Models of Hepatocellular Carcinoma and Biomarker Strategy, Cancers (Basel), vol.2, pp.1441-1452, 2010.

M. G. Hollingshead, M. C. Alley, R. F. Camalier, B. J. Abbott, J. G. Mayo et al., In vivo cultivation of tumor cells in hollow fibers, Life Sci, vol.57, issue.95, pp.254-258, 1995.

P. Merle, Epidemiology

, Cancer/Radiothérapie, vol.9, pp.452-457, 2005.

I. K. Gordon and C. Khanna, Modeling opportunities in comparative oncology for drug development, ILAR J, vol.51, pp.214-220, 2010.

J. H. Kang, T. Mori, T. Niidome, and Y. Katayama, A syngeneic hepatocellular carcinoma model rapidly and simply prepared using a hydrodynamics-based procedure, Vet J. Elsevier Ltd, vol.181, pp.336-339, 2009.

F. Liu, Y. Song, and D. Liu, Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA, Gene Ther, vol.6, pp.1258-1266, 1999.

S. L. Walker, J. George, L. W. Hebbard, L. Qiao, Y. Li et al., Molecular Aspects of Hepatocellular Carcinoma, pp.116-128, 2012.

S. S. Pinho, S. Carvalho, J. Cabral, . Reis-c-a, and F. Gärtner, Canine tumors: a spontaneous animal model of human carcinogenesis, Transl Res, vol.159, pp.165-72, 2012.

H. R. Cho, J. W. Choi, H. Kim, Y. S. Song, G. M. Kim et al., Sprague-Dawley rats bearing McA-RH7777 cells for study of hepatoma and transarterial chemoembolization, Anticancer Res, vol.33, pp.223-230, 2013.

G. Mclennan, S. L. Bennett, S. Ju, A. Babsky, N. Bansal et al., Tumor response and apoptosis of N1-S1 rodent hepatomas in response to intra-arterial and intravenous benzamide riboside, Cardiovasc Intervent Radiol, vol.35, pp.645-52, 2012.

X. Li, C. Zheng, G. Feng, C. Zhuo, J. Zhao et al., An implantable rat liver tumor model for experimental transarterial chemoembolization therapy and its imaging, World J Gastroenterol, vol.8, pp.1035-1039, 2002.

S. De-minicis, T. Kisseleva, H. Francis, G. S. Baroni, A. Benedetti et al., Liver carcinogenesis: Rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis. Editrice Gastroenterologica Italiana, vol.45, pp.450-459, 2013.

A. Mantovani, Cancer: an infernal triangle, Nature, vol.448, pp.1-2, 2007.

A. Y. Sheu, Z. Zhang, R. A. Omary, and A. C. Larson, Invasive catheterization of the hepatic artery for Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.212

, preclinical investigation of liver-directed therapies in rodent models of liver cancer, Am J Transl Res, vol.5, pp.269-278, 2013.

T. T. Than, J. Sitzmann, S. Li, P. Lin, and L. B. Grochow, A method for hepatic arterial perfusion studies in the rat, J Surg Res, vol.47, pp.251-254, 1989.

X. Li, Y. Wang, X. Zhou, Y. Guan, and C. Tang, Catheterization of the hepatic artery via the left common carotid artery in rats, Cardiovasc Intervent Radiol, vol.29, pp.1073-1079, 2006.

B. Lindell, K. Aronsen, B. Nosslin, and U. Rothman, Studies in pharmacokinetics and tolerance of substances temporarily retained in the liver by microsphere embolization, Ann Surg, vol.187, pp.95-104, 1978.

J. Qian, J. Truebenbach, F. Graepler, P. Pereira, P. Huppert et al., Application of polylactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma, World J Gastroenterol, vol.9, pp.94-102, 2003.

J. Qian, D. Vossoughi, D. Woitaschek, E. Oppermann, W. O. Bechstein et al., Combined transarterial chemoembolization and arterial administration of Bletilla striata in treatment of liver tumor in rats, World J Gastroenterol, vol.9, pp.2676-2680, 2003.

K. Shinozaki, O. Ebert, C. Kournioti, Y. Tai, and S. Woo, Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus, Mol Ther, vol.9, pp.368-76, 2004.

K. Shinozaki, O. Ebert, and S. Woo, Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV, Hepatology, vol.41, pp.196-203, 2005.

J. Altomonte, R. Braren, S. Schulz, S. Marozin, E. J. Rummeny et al., Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats, Hepatology, vol.48, pp.1864-1873, 2008.

E. Garin, B. Denizot, J. Roux, N. Noiret, N. Lepareur et al., Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat, Lab Anim, vol.39, pp.314-334, 2005.

S. Ju, G. Mclennan, S. L. Bennett, Y. Liang, L. Bonnac et al., Technical aspects of imaging and transfemoral arterial treatment of N1-S1 tumors in rats: an appropriate model to test the biology and therapeutic response to transarterial treatments of liver cancers, J Vasc Interv Radiol. SIR, vol.20, pp.410-414, 2009.

H. Maruyama, S. Matsutani, H. Saisho, N. Kamiyama, Y. Mine et al., Sonographic shift of hypervascular liver tumor on blood pool harmonic images with definity: Time-related changes of contrast-enhanced appearance in rabbit VX2 tumor under extra-low acoustic power, Eur J Radiol, vol.56, pp.60-65, 2005.

P. Rous and J. Beard, The progression to carcinoma of virus-induced rabbit papillomas (Shope), J Exp Med, vol.62, pp.523-571, 1935.

J. G. Kidd and P. Rous, A transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus in masked or altered form, J Exp Med, vol.71, pp.813-851, 1940.

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.213

S. Virmani, K. R. Harris, B. Szolc-kowalska, T. Paunesku, G. E. Woloschak et al., Comparison of Two Different Methods for Inoculating VX2 Tumors in Rabbit Livers and Hind Limbs, J Vasc Interv Radiol, vol.19, pp.931-936, 2008.

J. H. Chen, Y. C. Lin, Y. S. Huang, T. J. Chen, W. Y. Lin et al., Induction of VX2 carcinoma in rabbit liver: comparison of two inoculation methods, Lab Anim, vol.38, pp.79-84, 2004.

J. H. Sun, Y. L. Zhang, C. H. Nie, X. B. Yu, H. Y. Xie et al., Considerations for two inoculation methods of rabbit hepatic tumors: Pathology and image features, Exp Ther Med, vol.3, pp.386-390, 2012.

K. H. Lee, E. Liapi, M. Buijs, J. Vossen, K. Hong et al., Considerations for Implantation Site of VX2 Carcinoma into Rabbit Liver, J Vasc Interv Radiol. SIR, vol.20, pp.113-117, 2009.

F. Pascale, S. H. Ghegediban, M. Bonneau, L. Bedouet, J. Namur et al., Modified model of VX2 tumor overexpressing vascular endothelial growth factor, J Vasc Interv Radiol, vol.23, pp.809-817, 2012.

Z. P. Yan, G. Lin, H. Y. Zhao, and Y. H. Dong, An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer, Cancer, vol.72, pp.3210-3215, 1993.

M. N. Chamberlain, B. N. Gray, J. Heggie, R. L. Chmiel, and R. C. Bennett, Hepatic metastases-a physiological approach to treatment, Br J Surg, vol.70, pp.596-598, 1983.

Y. Yumoto, K. Jinno, S. Inatsuki, S. Moriwaki, T. Hanafusa et al., Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution, Cancer Chemother Pharmacol, vol.31, pp.128-136, 1992.

P. L. Roberson, R. K. Ten-haken, D. L. Mcshan, P. E. Mckeever, and W. D. Ensminger, Three-dimensional tumor dosimetry for hepatic yttrium-90-microsphere therapy, J Nucl Med, vol.33, pp.735-743, 1992.

K. M. Pillai, P. E. Mckeever, C. A. Knutsen, P. A. Terrio, D. M. Prieskorn et al., Microscopic analysis of arterial microsphere distribution in rabbit liver and hepatic VX2 tumor, Sel Cancer Ther, vol.7, pp.39-48, 1991.

M. Tian, W. Lu, R. Zhang, C. Xiong, J. Ensor et al., Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET/CT study in a rabbit VX2 liver cancer model, Mol Imaging Biol, vol.15, pp.614-624, 2013.

M. Chang and W. Lin, The Effect of Intratumoral Injection of 188 Re-Microspheres on the Hematologic , Hepatic and Renal Functions in the Treatment of VX2 Hepatic Tumor : An Animal Study, Ann Nucl Med Sci, vol.20, pp.187-192, 2007.

D. Yu, H. Chang, C. Sommer, W. Qu, W. Xu et al., Efficacy and safety of percutaneous microwave coagulation therapy followed by (125)I seed brachytherapy for VX2 hepatic tumors in a rabbit model, Exp Ther Med, vol.6, pp.159-163, 2013.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.214

K. V. Stribley, B. N. Gray, R. L. Chmiel, J. Heggie, and R. C. Bennett, Internal radiotherapy for hepatic metastases I: The homogeneity of hepatic arterial blood flow, J Surg Res, vol.34, pp.17-24, 1983.

R. G. Selwyn, M. A. Avila-rodriguez, A. K. Converse, J. A. Hampel, C. J. Jaskowiak et al., 18F-labeled resin microspheres as surrogates for 90Y resin microspheres used in the treatment of hepatic tumors: a radiolabeling and PET validation study, Phys Med Biol, vol.52, pp.7397-408, 2007.

J. Namur, M. Wassef, J. M. Millot, A. L. Lewis, M. Manfait et al., Drug-eluting Beads for Liver Embolization: Concentration of Doxorubicin in Tissue and in Beads in a Pig Model, J Vasc Interv Radiol, vol.21, pp.259-267, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00473048

J. Dürager, Establishing a hepatocellular carcinoma model in pigs. Medical University of Graz, 2010.

Y. Wang, X. Li, X. Zhou, and C. Tang, N-Nitrosodiethylamine-Induced Pig Liver Hepatocellular Carcinoma Model: MRI with Gd-BOPTA enhancement, Proc Intl Soc Mag Reson Med, vol.16, p.3816, 2008.

S. J. Adam, K. N. Kuzmuk, J. F. Zachary, L. B. Schook, and C. M. Counter, Genetic induction of tumorigenesis in swine, Oncogene, vol.26, pp.1038-1083, 2007.

C. Gouillat, D. Manganas, F. Zoulim, D. Vitrey, G. Saguier et al., Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma, J Hepatol, vol.26, pp.1324-1330, 1997.

C. T. Burke, J. M. Cullen, A. State, S. Gadi, K. Wilber et al., Development of an animal model for radiofrequency ablation of primary, virally induced hepatocellular carcinoma in the woodchuck, J Vasc Interv Radiol, vol.22, pp.1613-1618, 2011.

J. A. Kolthammer, D. J. Corn, N. Tenley, C. Wu, H. Tian et al., PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline, Eur J Nucl Med Mol Imaging, vol.38, pp.1248-1256, 2011.

M. Unoura, K. Kobayashi, K. Fukuoka, F. Matsushita, H. Morimoto et al., Establishment of a cell line from a woodchuck hepatocellular carcinoma, Hepatology, vol.5, pp.1106-1111, 1985.

K. Abe, T. Kurata, K. Yamada, H. Okumura, and T. Shikata, Establishment and characterization of a woodchuck hepatocellular carcinoma cell line (WH44KA), Jpn J Cancer Res, vol.79, pp.342-349, 1988.

S. Ohnishi, H. Aoyama, J. Shiga, Y. Itai, T. Moriyama et al., Establishment of a new cell line from a woodchuck hepatocellular carcinoma, Hepatology, vol.8, pp.104-107, 1988.

R. Q. Yan, J. J. Su, D. R. Huang, Y. C. Gan, C. Yang et al., Human hepatitis B virus and hepatocellular carcinoma I. Experimental infection of tree shrews with hepatitis B virus, J Cancer Res Clin Oncol, vol.122, pp.283-288, 1996.

R. Q. Yan, J. J. Su, D. R. Huang, Y. C. Gan, C. Yang et al., Human hepatitis B virus and hepatocellular carcinoma II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1, J Cancer Res Clin Oncol, vol.122, pp.289-295, 1996.

, Verger Elise | Les 68

. Ga, , p.188

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.215

P. L. Marion, M. J. Van-davelaar, S. S. Knight, F. H. Salazar, G. Garcia et al., Hepatocellular carcinoma in ground squirrels persistently infected with ground squirrel hepatitis virus, Proc Natl Acad Sci, vol.83, pp.4543-4546, 1986.

K. Lapis, J. Bocsi, F. Timar, P. Lapis, U. P. Thorgeirsson et al., J Pathol, vol.181, pp.439-443, 1997.

F. Gyorkey, J. L. Melnick, R. Mirkovic, P. Cabral-g-a,-gyorkey, and F. B. Hollinger, Experimental carcinoma of liver in macaque monkeys exposed to diethylnitrosamine and hepatitis B virus, J Natl Cancer Inst, vol.59, pp.1451-1467, 1977.

K. Hansen and C. Khanna, Spontaneous and genetically engineered animal models; use in preclinical cancer drug development, Eur J Cancer, vol.40, pp.858-80, 2004.

M. C. Paoloni and C. Khanna, Comparative Oncology Today, Vet Clin North Am Small Anim Pract, vol.37, pp.1023-1032, 2007.

C. Khanna, C. London, D. Vail, C. Mazcko, and S. Hirschfeld, Guiding the optimal translation of new cancer treatments from canine to human cancer patients, Clin Cancer Res, vol.15, pp.5671-5678, 2009.

M. C. Paoloni, A. Tandle, C. Mazcko, E. Hanna, S. Kachala et al., Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of TNF? to cancer vasculature, PLoS One, vol.4, 2009.

I. Gordon, M. Paoloni, C. Mazcko, and C. Khanna, The comparative oncology trials consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway, PLoS Med, vol.6, pp.2-6, 2009.

J. M. Liptak, W. S. Dernell, and S. J. Withrow, Liver tumors in cats and dogs, Compend Contin Educ Pract Vet, vol.26, pp.50-57, 2004.

J. M. Liptak, W. S. Dernell, E. Monnet, B. E. Powers, A. M. Bachand et al., Massive hepatocellular carcinoma in dogs: 48 cases (1992-2002), J Am Vet Med Assoc, vol.225, pp.1225-1255, 2004.

B. Rivera, K. Ahrar, M. M. Kangasniemi, J. D. Hazle, and R. E. Price, Canine transmissible venereal tumor: a large-animal transplantable tumor model, Comp Med, vol.55, pp.335-343, 2005.

M. Michishita, S. Ezaki, K. Ogihara, Y. Naya, D. Azakami et al., Identification of tumor-initiating cells in a canine hepatocellular carcinoma cell line, Res Vet Sci. Elsevier Ltd, vol.96, pp.315-322, 2014.

I. Wollner, C. Knutsen, P. Smith, D. Prieskorn, C. Chrisp et al., Effects of hepatic arterial yttrium 90 glass microspheres in dogs, Cancer, vol.61, pp.1336-1344, 1988.

I. S. Wollner, C. A. Knutsen, K. A. Ullrich, C. E. Chrisp, J. E. Juni et al., Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs, Cancer Res, vol.47, pp.3285-3290, 1987.

-. Re and . Sbmp, agent radiothéranostique des tumeurs hépatiques, p.216

H. J. Rapp, W. Churchill, B. S. Kronman, R. T. Rolley, W. G. Hammond et al., Antigenicity of a new diethylnitrosamine-induced transplantable guinea pig hepatoma: pathology and formation of ascites variant, J Natl Cancer Inst, vol.41, pp.1-11, 1968.

M. Mirowski, M. Rozalski, U. Krajewska, M. Hanausek, and R. Wierzbicki, Expression of 65-kDa oncofetal protein in experimental hepatoma after anticancer therapy, Neoplasma, vol.44, pp.85-89, 1997.

H. Feitsma and E. Cuppen, Zebrafish as a cancer model, Mol Cancer Res, vol.6, pp.685-94, 2008.

J. Lu, Y. Hsia, H. Tu, Y. Hsiao, Y. Wang et al., Liver development and cancer formation in zebrafish, Birth Defects Res C Embryo Today, vol.93, pp.157-72, 2011.

J. J. Vajo, L. Ashley, D. E. Poeltl, . Bailey-r-a, and H. M. Clark, Facile electroreduction of perrhenate in weakly acidic citrate and oxalate media, Inorg Chem, vol.20, pp.3328-3333, 1981.

A. Boschi, A. Duatti, and L. Uccelli, Development of Technetium-99m and Rhenium-188

, Radiopharmaceuticals Containing a Terminal Metal-Nitrido Multiple Bond for Diagnosis and Therapy, Top Curr Chem, vol.252, pp.85-115, 2005.

A. Boschi, C. Bolzati, L. Uccelli, and A. Duatti, High-yield synthesis of the terminal 188Re?N multiple bond from generator-produced [188ReO4], Nucl Med Biol, vol.30, pp.381-387, 2003.

B. Baur, C. Solbach, E. Andreolli, G. Winter, H. J. Machulla et al., Synthesis, radiolabelling and in vitro characterization of the gallium-68-, yttrium-90-and lutetium-177-labelled PSMA Ligand, CHX-A"-DTPA-DUPA-Pep, Pharmaceuticals, vol.7, pp.517-529, 2014.

E. W. Price and C. Orvig, Matching chelators to radiometals for radiopharmaceuticals, Chem Soc Rev, vol.43, pp.260-90, 2014.

M. Nijkeuter and M. V. Huisman, Diagnostic methods in pulmonary embolism, Eur J Intern Med, vol.16, pp.247-256, 2005.